{"id":14171,"date":"2026-02-06T11:17:00","date_gmt":"2026-02-06T10:17:00","guid":{"rendered":"https:\/\/okomeds.com\/?p=14171"},"modified":"2026-02-06T11:17:00","modified_gmt":"2026-02-06T10:17:00","slug":"pros-and-patient-questionnaires-in-global-studies-how-to-avoid-putting-your-endpoint-at-risk-because-of-language","status":"publish","type":"post","link":"https:\/\/okomeds.com\/es\/pros-and-patient-questionnaires-in-global-studies-how-to-avoid-putting-your-endpoint-at-risk-because-of-language\/","title":{"rendered":"PROs and patient questionnaires in global studies: how to avoid putting your endpoint at risk because of language"},"content":{"rendered":"<p>More and more clinical trials depend on what patients report: symptoms, quality of life, and the impact of treatment on their daily lives. These are PROs in<a href=\"https:\/\/okomeds.com\/translation-cro\/\" target=\"_blank\" rel=\"noopener\"> clinical trials<\/a>, and in 2026 they sit at the centre of the regulatory conversation.<\/p>\n<p>The problem is that a poorly translated PRO can put your endpoint at risk: if a patient in Spain understands one thing, a patient in another country something different, and a patient in Latin America something else entirely, your data ceases to be comparable.<\/p>\n<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_82_2 counter-hierarchy ez-toc-counter ez-toc-grey ez-toc-container-direction\">\n<div class=\"ez-toc-title-container\">\n<p class=\"ez-toc-title\" style=\"cursor:inherit\">Table of Contents<\/p>\n<span class=\"ez-toc-title-toggle\"><a href=\"#\" class=\"ez-toc-pull-right ez-toc-btn ez-toc-btn-xs ez-toc-btn-default ez-toc-toggle\" aria-label=\"Alternar tabla de contenidos\"><span class=\"ez-toc-js-icon-con\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/span><\/a><\/span><\/div>\n<nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/okomeds.com\/es\/pros-and-patient-questionnaires-in-global-studies-how-to-avoid-putting-your-endpoint-at-risk-because-of-language\/#The_new_regulatory_context_of_PROs\" >The new regulatory context of PROs<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/okomeds.com\/es\/pros-and-patient-questionnaires-in-global-studies-how-to-avoid-putting-your-endpoint-at-risk-because-of-language\/#What_does_a_%E2%80%9CPRO_linguistic_strategy%E2%80%9D_really_mean\" >What does a \u201cPRO linguistic strategy\u201d really mean?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/okomeds.com\/es\/pros-and-patient-questionnaires-in-global-studies-how-to-avoid-putting-your-endpoint-at-risk-because-of-language\/#Typical_risks_when_the_linguistic_aspect_is_not_properly_managed\" >Typical risks when the linguistic aspect is not properly managed<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/okomeds.com\/es\/pros-and-patient-questionnaires-in-global-studies-how-to-avoid-putting-your-endpoint-at-risk-because-of-language\/#Recommended_process_of_linguistic_and_cultural_adaptation\" >Recommended process of linguistic and cultural adaptation<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/okomeds.com\/es\/pros-and-patient-questionnaires-in-global-studies-how-to-avoid-putting-your-endpoint-at-risk-because-of-language\/#PROs_in_ePRO_the_additional_challenge\" >PROs in ePRO: the additional challenge<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-6\" href=\"https:\/\/okomeds.com\/es\/pros-and-patient-questionnaires-in-global-studies-how-to-avoid-putting-your-endpoint-at-risk-because-of-language\/#Benefits_for_the_CRO_of_professionalising_the_linguistic_aspect\" >Benefits for the CRO of professionalising the linguistic aspect<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-7\" href=\"https:\/\/okomeds.com\/es\/pros-and-patient-questionnaires-in-global-studies-how-to-avoid-putting-your-endpoint-at-risk-because-of-language\/#Quick_checklist_for_PROs_in_international_trials\" >Quick checklist for PROs in international trials<\/a><\/li><\/ul><\/nav><\/div>\n<h2><span class=\"ez-toc-section\" id=\"The_new_regulatory_context_of_PROs\"><\/span>The new regulatory context of PROs<span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Health authorities have been publishing guidelines on how PROs should be developed and used in medicines development for years. In some therapeutic areas, such as oncology, specific recommendations already exist on how to define and use these instruments.<\/p>\n<p>In Europe, agencies are promoting the systematic use of patient experience data, including PROs and other quality of life instruments, as part of the evidence supporting benefit-risk decisions.<\/p>\n<p>The implication for CROs is clear: it is no longer enough to simply \u201chave a questionnaire\u201d. They must demonstrate that these PROs in clinical trials work equally well in all languages used in the study.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"What_does_a_%E2%80%9CPRO_linguistic_strategy%E2%80%9D_really_mean\"><\/span>What does a \u201cPRO linguistic strategy\u201d really mean?<span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>A solid strategy goes beyond simply translating the instrument. It includes:<\/p>\n<ul>\n<li>Selecting instruments that are validated for the target language and population.<\/li>\n<li>Adapting the items culturally when necessary, without changing the concept they measure.<\/li>\n<li>Maintaining strict version traceability, especially when ePRO is involved.<\/li>\n<li>Planning from the outset how PROs in clinical trials will be integrated into the operational flow of the study.<\/li>\n<li>Regulatory guidelines emphasise that patient questionnaires must measure the same thing in all cultural contexts where they are applied. Otherwise, cross-country comparisons become fragile.<\/li>\n<\/ul>\n<h2><span class=\"ez-toc-section\" id=\"Typical_risks_when_the_linguistic_aspect_is_not_properly_managed\"><\/span>Typical risks when the linguistic aspect is not properly managed<span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Some common problems a CRO sees:<\/p>\n<p>\u201cAd hoc\u201d translations carried out by internal staff without a formal validation process.<\/p>\n<p>Improvised changes to items to \u201cadjust\u201d them to the country, without reviewing the psychometric impact.<\/p>\n<p>Misaligned versions between paper and ePRO, with text in the app that differs from the approved PDF.<\/p>\n<p>Confusing instructions that cause erratic response patterns or high levels of missing data.<\/p>\n<p>Any of these situations may cause a reviewer to question the validity of your PROs in clinical trials as endpoints or key secondary endpoints.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Recommended_process_of_linguistic_and_cultural_adaptation\"><\/span>Recommended process of linguistic and cultural adaptation<span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>International best practice for PROs and other patient questionnaires includes several phases:<\/p>\n<p><strong>Direct translation in duplicate<\/strong><\/p>\n<p>Two native translators of the target language, experts in health, work independently.<\/p>\n<p><strong>Reconciliation<\/strong><\/p>\n<p>A senior linguist combines both versions and agrees on the best formulation for each item.<\/p>\n<p><strong>Back-translation<\/strong><\/p>\n<p>A different translator, unfamiliar with the original, translates the text back into the source language to check for deviations in meaning.<\/p>\n<p><strong>Clinical expert review<\/strong><\/p>\n<p>Specialists review the items to ensure they maintain the clinical intent of the instrument.<\/p>\n<p><strong>Cognitive interviews with patients<\/strong><\/p>\n<p>Patients from the target population complete the questionnaire and explain what they understand by each item; the text is adjusted based on their comments.<\/p>\n<p><strong>Version closure and documentation<\/strong><\/p>\n<p>The entire process is documented: who has participated, what decisions have been made, and what the final approved version is.<\/p>\n<p>This approach not only protects your data; it also gives you very strong arguments to defend PROs in clinical trials before a regulator.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"PROs_in_ePRO_the_additional_challenge\"><\/span>PROs in ePRO: the additional challenge<span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>When the questionnaire is converted to electronic format (ePRO), additional challenges arise:<\/p>\n<ul>\n<li>Ensuring that sentences fit on small screens without being cut off in a confusing way.<\/li>\n<li>Validating that format changes do not alter comprehension or response patterns.<\/li>\n<li>Keeping all versions of the application synchronised with the approved language version.<\/li>\n<li>Poor interface design can be just as problematic as a bad translation, especially in patients with low health literacy or little familiarity with digital devices.<\/li>\n<\/ul>\n<h2><span class=\"ez-toc-section\" id=\"Benefits_for_the_CRO_of_professionalising_the_linguistic_aspect\"><\/span>Benefits for the CRO of professionalising the linguistic aspect<span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>When a CRO invests in a solid PROs strategy in multilingual clinical trials, it:<\/p>\n<ul>\n<li>Reduces regulatory queries relating to the validity of patient endpoints.<\/li>\n<li>Minimises rework on questionnaires, applications, and training materials.<\/li>\n<li>Improves data quality, with fewer inconsistent responses and less missing data.<\/li>\n<li>Strengthens its value proposition to sponsors who want a well-integrated and defensible \u201cpatient voice\u201d.<\/li>\n<\/ul>\n<h2><span class=\"ez-toc-section\" id=\"Quick_checklist_for_PROs_in_international_trials\"><\/span>Quick checklist for PROs in international trials<span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Before closing your PROs plan, verify that:<\/p>\n<p>&#8211; The instrument is validated or there is a validation plan in each key language.<\/p>\n<p>&#8211; Translation and cultural adaptation documentation exists, not just a \u201ctranslated version\u201d.<\/p>\n<p>&#8211; Paper and ePRO use exactly the same wording in each language.<\/p>\n<p>&#8211; Monitors and coordinators are well aware of the purpose of each questionnaire and how to explain it to the patient.<\/p>\n<p>-You have a centralised repository with all controlled versions of the questionnaire.<\/p>\n<p>-You can clearly describe the process followed for your PROs in clinical trials.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>More and more clinical trials depend on what patients report: symptoms, quality of life, and the impact of treatment on their daily lives. These are PROs in clinical trials, and in 2026 they sit at the centre of the regulatory conversation. The problem is that&#8230;<\/p>\n","protected":false},"author":13,"featured_media":14173,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[5],"tags":[],"class_list":["post-14171","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-clinical-research"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>PROs and patient questionnaires in global studies: how to avoid putting your endpoint at risk because of language - Okomeds<\/title>\n<meta name=\"description\" content=\"Avoid putting endpoints at risk due to language failures: design and adapt your PROs well in global clinical trials and protect data quality.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/okomeds.com\/pros-and-patient-questionnaires-in-global-studies-how-to-avoid-putting-your-endpoint-at-risk-because-of-language\/\" \/>\n<meta property=\"og:locale\" content=\"es_ES\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"PROs and patient questionnaires in global studies: how to avoid putting your endpoint at risk because of language - Okomeds\" \/>\n<meta property=\"og:description\" content=\"Avoid putting endpoints at risk due to language failures: design and adapt your PROs well in global clinical trials and protect data quality.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/okomeds.com\/pros-and-patient-questionnaires-in-global-studies-how-to-avoid-putting-your-endpoint-at-risk-because-of-language\/\" \/>\n<meta property=\"og:site_name\" content=\"Okomeds\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/okomeds\" \/>\n<meta property=\"article:published_time\" content=\"2026-02-06T10:17:00+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/okomeds.com\/wp-content\/uploads\/2026\/02\/PROs-in-clinical-trials-1.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"560\" \/>\n\t<meta property=\"og:image:height\" content=\"315\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Roc\u00edo Gonz\u00e1lez\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@okomeds\" \/>\n<meta name=\"twitter:site\" content=\"@okomeds\" \/>\n<meta name=\"twitter:label1\" content=\"Escrito por\" \/>\n\t<meta name=\"twitter:data1\" content=\"Roc\u00edo Gonz\u00e1lez\" \/>\n\t<meta name=\"twitter:label2\" content=\"Tiempo de lectura\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutos\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/okomeds.com\\\/pros-and-patient-questionnaires-in-global-studies-how-to-avoid-putting-your-endpoint-at-risk-because-of-language\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/okomeds.com\\\/pros-and-patient-questionnaires-in-global-studies-how-to-avoid-putting-your-endpoint-at-risk-because-of-language\\\/\"},\"author\":{\"name\":\"Roc\u00edo Gonz\u00e1lez\",\"@id\":\"https:\\\/\\\/okomeds.com\\\/#\\\/schema\\\/person\\\/e7e418e05e40977a56bd9ccff6a3a348\"},\"headline\":\"PROs and patient questionnaires in global studies: how to avoid putting your endpoint at risk because of language\",\"datePublished\":\"2026-02-06T10:17:00+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/okomeds.com\\\/pros-and-patient-questionnaires-in-global-studies-how-to-avoid-putting-your-endpoint-at-risk-because-of-language\\\/\"},\"wordCount\":812,\"publisher\":{\"@id\":\"https:\\\/\\\/okomeds.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/okomeds.com\\\/pros-and-patient-questionnaires-in-global-studies-how-to-avoid-putting-your-endpoint-at-risk-because-of-language\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/okomeds.com\\\/wp-content\\\/uploads\\\/2026\\\/02\\\/PROs-in-clinical-trials-1.jpg\",\"articleSection\":[\"Clinical Research\"],\"inLanguage\":\"es\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/okomeds.com\\\/pros-and-patient-questionnaires-in-global-studies-how-to-avoid-putting-your-endpoint-at-risk-because-of-language\\\/\",\"url\":\"https:\\\/\\\/okomeds.com\\\/pros-and-patient-questionnaires-in-global-studies-how-to-avoid-putting-your-endpoint-at-risk-because-of-language\\\/\",\"name\":\"PROs and patient questionnaires in global studies: how to avoid putting your endpoint at risk because of language - Okomeds\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/okomeds.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/okomeds.com\\\/pros-and-patient-questionnaires-in-global-studies-how-to-avoid-putting-your-endpoint-at-risk-because-of-language\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/okomeds.com\\\/pros-and-patient-questionnaires-in-global-studies-how-to-avoid-putting-your-endpoint-at-risk-because-of-language\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/okomeds.com\\\/wp-content\\\/uploads\\\/2026\\\/02\\\/PROs-in-clinical-trials-1.jpg\",\"datePublished\":\"2026-02-06T10:17:00+00:00\",\"description\":\"Avoid putting endpoints at risk due to language failures: design and adapt your PROs well in global clinical trials and protect data quality.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/okomeds.com\\\/pros-and-patient-questionnaires-in-global-studies-how-to-avoid-putting-your-endpoint-at-risk-because-of-language\\\/#breadcrumb\"},\"inLanguage\":\"es\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/okomeds.com\\\/pros-and-patient-questionnaires-in-global-studies-how-to-avoid-putting-your-endpoint-at-risk-because-of-language\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\\\/\\\/okomeds.com\\\/pros-and-patient-questionnaires-in-global-studies-how-to-avoid-putting-your-endpoint-at-risk-because-of-language\\\/#primaryimage\",\"url\":\"https:\\\/\\\/okomeds.com\\\/wp-content\\\/uploads\\\/2026\\\/02\\\/PROs-in-clinical-trials-1.jpg\",\"contentUrl\":\"https:\\\/\\\/okomeds.com\\\/wp-content\\\/uploads\\\/2026\\\/02\\\/PROs-in-clinical-trials-1.jpg\",\"width\":560,\"height\":315,\"caption\":\"PROs in clinical trials\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/okomeds.com\\\/pros-and-patient-questionnaires-in-global-studies-how-to-avoid-putting-your-endpoint-at-risk-because-of-language\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/okomeds.com\\\/es\\\/inicio-2-2\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"PROs and patient questionnaires in global studies: how to avoid putting your endpoint at risk because of language\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/okomeds.com\\\/#website\",\"url\":\"https:\\\/\\\/okomeds.com\\\/\",\"name\":\"Okomeds\",\"description\":\"Agencia de traducci\u00f3n m\u00e9dica y de salud\",\"publisher\":{\"@id\":\"https:\\\/\\\/okomeds.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/okomeds.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"es\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/okomeds.com\\\/#organization\",\"name\":\"Okodia\",\"url\":\"https:\\\/\\\/okomeds.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\\\/\\\/okomeds.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/okomeds.com\\\/wp-content\\\/uploads\\\/2015\\\/12\\\/logo-okomeds.png\",\"contentUrl\":\"https:\\\/\\\/okomeds.com\\\/wp-content\\\/uploads\\\/2015\\\/12\\\/logo-okomeds.png\",\"width\":300,\"height\":77,\"caption\":\"Okodia\"},\"image\":{\"@id\":\"https:\\\/\\\/okomeds.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/okomeds\",\"https:\\\/\\\/x.com\\\/okomeds\",\"https:\\\/\\\/www.linkedin.com\\\/company\\\/okomeds\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/okomeds.com\\\/#\\\/schema\\\/person\\\/e7e418e05e40977a56bd9ccff6a3a348\",\"name\":\"Roc\u00edo Gonz\u00e1lez\",\"url\":\"https:\\\/\\\/okomeds.com\\\/es\\\/author\\\/rociookodia-com\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"PROs and patient questionnaires in global studies: how to avoid putting your endpoint at risk because of language - Okomeds","description":"Avoid putting endpoints at risk due to language failures: design and adapt your PROs well in global clinical trials and protect data quality.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/okomeds.com\/pros-and-patient-questionnaires-in-global-studies-how-to-avoid-putting-your-endpoint-at-risk-because-of-language\/","og_locale":"es_ES","og_type":"article","og_title":"PROs and patient questionnaires in global studies: how to avoid putting your endpoint at risk because of language - Okomeds","og_description":"Avoid putting endpoints at risk due to language failures: design and adapt your PROs well in global clinical trials and protect data quality.","og_url":"https:\/\/okomeds.com\/pros-and-patient-questionnaires-in-global-studies-how-to-avoid-putting-your-endpoint-at-risk-because-of-language\/","og_site_name":"Okomeds","article_publisher":"https:\/\/www.facebook.com\/okomeds","article_published_time":"2026-02-06T10:17:00+00:00","og_image":[{"width":560,"height":315,"url":"https:\/\/okomeds.com\/wp-content\/uploads\/2026\/02\/PROs-in-clinical-trials-1.jpg","type":"image\/jpeg"}],"author":"Roc\u00edo Gonz\u00e1lez","twitter_card":"summary_large_image","twitter_creator":"@okomeds","twitter_site":"@okomeds","twitter_misc":{"Escrito por":"Roc\u00edo Gonz\u00e1lez","Tiempo de lectura":"4 minutos"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/okomeds.com\/pros-and-patient-questionnaires-in-global-studies-how-to-avoid-putting-your-endpoint-at-risk-because-of-language\/#article","isPartOf":{"@id":"https:\/\/okomeds.com\/pros-and-patient-questionnaires-in-global-studies-how-to-avoid-putting-your-endpoint-at-risk-because-of-language\/"},"author":{"name":"Roc\u00edo Gonz\u00e1lez","@id":"https:\/\/okomeds.com\/#\/schema\/person\/e7e418e05e40977a56bd9ccff6a3a348"},"headline":"PROs and patient questionnaires in global studies: how to avoid putting your endpoint at risk because of language","datePublished":"2026-02-06T10:17:00+00:00","mainEntityOfPage":{"@id":"https:\/\/okomeds.com\/pros-and-patient-questionnaires-in-global-studies-how-to-avoid-putting-your-endpoint-at-risk-because-of-language\/"},"wordCount":812,"publisher":{"@id":"https:\/\/okomeds.com\/#organization"},"image":{"@id":"https:\/\/okomeds.com\/pros-and-patient-questionnaires-in-global-studies-how-to-avoid-putting-your-endpoint-at-risk-because-of-language\/#primaryimage"},"thumbnailUrl":"https:\/\/okomeds.com\/wp-content\/uploads\/2026\/02\/PROs-in-clinical-trials-1.jpg","articleSection":["Clinical Research"],"inLanguage":"es"},{"@type":"WebPage","@id":"https:\/\/okomeds.com\/pros-and-patient-questionnaires-in-global-studies-how-to-avoid-putting-your-endpoint-at-risk-because-of-language\/","url":"https:\/\/okomeds.com\/pros-and-patient-questionnaires-in-global-studies-how-to-avoid-putting-your-endpoint-at-risk-because-of-language\/","name":"PROs and patient questionnaires in global studies: how to avoid putting your endpoint at risk because of language - Okomeds","isPartOf":{"@id":"https:\/\/okomeds.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/okomeds.com\/pros-and-patient-questionnaires-in-global-studies-how-to-avoid-putting-your-endpoint-at-risk-because-of-language\/#primaryimage"},"image":{"@id":"https:\/\/okomeds.com\/pros-and-patient-questionnaires-in-global-studies-how-to-avoid-putting-your-endpoint-at-risk-because-of-language\/#primaryimage"},"thumbnailUrl":"https:\/\/okomeds.com\/wp-content\/uploads\/2026\/02\/PROs-in-clinical-trials-1.jpg","datePublished":"2026-02-06T10:17:00+00:00","description":"Avoid putting endpoints at risk due to language failures: design and adapt your PROs well in global clinical trials and protect data quality.","breadcrumb":{"@id":"https:\/\/okomeds.com\/pros-and-patient-questionnaires-in-global-studies-how-to-avoid-putting-your-endpoint-at-risk-because-of-language\/#breadcrumb"},"inLanguage":"es","potentialAction":[{"@type":"ReadAction","target":["https:\/\/okomeds.com\/pros-and-patient-questionnaires-in-global-studies-how-to-avoid-putting-your-endpoint-at-risk-because-of-language\/"]}]},{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/okomeds.com\/pros-and-patient-questionnaires-in-global-studies-how-to-avoid-putting-your-endpoint-at-risk-because-of-language\/#primaryimage","url":"https:\/\/okomeds.com\/wp-content\/uploads\/2026\/02\/PROs-in-clinical-trials-1.jpg","contentUrl":"https:\/\/okomeds.com\/wp-content\/uploads\/2026\/02\/PROs-in-clinical-trials-1.jpg","width":560,"height":315,"caption":"PROs in clinical trials"},{"@type":"BreadcrumbList","@id":"https:\/\/okomeds.com\/pros-and-patient-questionnaires-in-global-studies-how-to-avoid-putting-your-endpoint-at-risk-because-of-language\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/okomeds.com\/es\/inicio-2-2\/"},{"@type":"ListItem","position":2,"name":"PROs and patient questionnaires in global studies: how to avoid putting your endpoint at risk because of language"}]},{"@type":"WebSite","@id":"https:\/\/okomeds.com\/#website","url":"https:\/\/okomeds.com\/","name":"Okomeds","description":"Agencia de traducci\u00f3n m\u00e9dica y de salud","publisher":{"@id":"https:\/\/okomeds.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/okomeds.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"es"},{"@type":"Organization","@id":"https:\/\/okomeds.com\/#organization","name":"Okodia","url":"https:\/\/okomeds.com\/","logo":{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/okomeds.com\/#\/schema\/logo\/image\/","url":"https:\/\/okomeds.com\/wp-content\/uploads\/2015\/12\/logo-okomeds.png","contentUrl":"https:\/\/okomeds.com\/wp-content\/uploads\/2015\/12\/logo-okomeds.png","width":300,"height":77,"caption":"Okodia"},"image":{"@id":"https:\/\/okomeds.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/okomeds","https:\/\/x.com\/okomeds","https:\/\/www.linkedin.com\/company\/okomeds"]},{"@type":"Person","@id":"https:\/\/okomeds.com\/#\/schema\/person\/e7e418e05e40977a56bd9ccff6a3a348","name":"Roc\u00edo Gonz\u00e1lez","url":"https:\/\/okomeds.com\/es\/author\/rociookodia-com\/"}]}},"_links":{"self":[{"href":"https:\/\/okomeds.com\/es\/wp-json\/wp\/v2\/posts\/14171","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/okomeds.com\/es\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/okomeds.com\/es\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/okomeds.com\/es\/wp-json\/wp\/v2\/users\/13"}],"replies":[{"embeddable":true,"href":"https:\/\/okomeds.com\/es\/wp-json\/wp\/v2\/comments?post=14171"}],"version-history":[{"count":2,"href":"https:\/\/okomeds.com\/es\/wp-json\/wp\/v2\/posts\/14171\/revisions"}],"predecessor-version":[{"id":14175,"href":"https:\/\/okomeds.com\/es\/wp-json\/wp\/v2\/posts\/14171\/revisions\/14175"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/okomeds.com\/es\/wp-json\/wp\/v2\/media\/14173"}],"wp:attachment":[{"href":"https:\/\/okomeds.com\/es\/wp-json\/wp\/v2\/media?parent=14171"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/okomeds.com\/es\/wp-json\/wp\/v2\/categories?post=14171"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/okomeds.com\/es\/wp-json\/wp\/v2\/tags?post=14171"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}